We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+6.09%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$722M
AUM Growth
+$48.2M
Cap. Flow
+$7.56M
Cap. Flow %
1.05%
Top 10 Hldgs %
54.91%
Holding
52
New
15
Increased
11
Reduced
7
Closed
14

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$35.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.8M
3
LRMR icon
Larimar Therapeutics
LRMR
+$24.8M
4
UTHR icon
United Therapeutics
UTHR
+$18.6M
5
VYGR icon
Voyager Therapeutics
VYGR
+$14.4M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$43.1M
2
ZGNX
Zogenix, Inc.
ZGNX
+$39.2M
3
PBYI icon
Puma Biotechnology
PBYI
+$34M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$33.2M
5
AIMT
Aimmune Therapeutics
AIMT
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 80.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$5.68B
$52.9M 7.33%
1,568,500
+28,678
+2% +$894K
KURA icon
2
Kura Oncology
KURA
$800M
$47.8M 6.63%
2,627,110
+246,264
+10% +$4.17M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$1.82B
$44.6M 6.18%
3,485,745
+164,572
+5% +$2.41M
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.28B
$42.9M 5.94%
7,478,275
– –
ONCE
5
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$41.4M 5.73%
500,000
-50,000
-9% -$3.86M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$36.8M 5.1%
758,000
+295,755
+64% +$10.8M
LRMR icon
7
Larimar Therapeutics
LRMR
$397M
$35.8M 4.96%
+291,667
New +$24.8M
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
$34.8M 4.83%
770,400
+33,769
+5% +$1.54M
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.43B
$30.5M 4.23%
+2,000,000
New +$35.7M
EXEL icon
10
Exelixis
EXEL
$13.3B
$28.7M 3.98%
1,334,793
+434,893
+48% +$8.99M
GBT
11
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$27.2M 3.77%
+602,200
New +$27.4M
XLRN
12
PUT
DELISTED
Acceleron Pharma
XLRN
$26.8M 3.71%
+552,300
New +$20.1M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$27.5B
$25.6M 3.55%
+260,100
New +$25.8M
FOMX
14
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$24M 3.32%
4,781,708
– –
NVCR icon
15
NovoCure
NVCR
$1.73B
$22.3M 3.1%
713,998
-39,483
-5% -$1.1M
FPRX
16
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$19.9M 2.76%
1,260,000
+391,900
+45% +$6.84M
UTHR icon
17
United Therapeutics
UTHR
$25.8B
$19.2M 2.66%
+169,639
New +$18.6M
VYGR icon
18
Voyager Therapeutics
VYGR
$183M
$14.3M 1.98%
+730,010
New +$14.4M
ALXN
19
DELISTED
Alexion Pharmaceuticals
ALXN
$13.7M 1.9%
+110,506
New +$12.9M
SVRA icon
20
Savara
SVRA
$1.12B
$13.3M 1.84%
1,174,541
+312,362
+36% +$3.13M
ARNA
21
DELISTED
Arena Pharmaceuticals Inc
ARNA
$13.2M 1.82%
302,000
-1,003,887
-77% -$43.1M
CYTK icon
22
Cytokinetics
CYTK
$10.5B
$12M 1.66%
+1,444,481
New +$12M
EXEL icon
23
CALL
Exelixis
EXEL
$13.3B
$10.8M 1.49%
+500,000
New +$10.3M
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.79B
$9.9M 1.37%
+1,473,609
New +$11.3M
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$681M
$9.64M 1.34%
340,784
-517,161
-60% -$18.4M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Great Point Partners held 52 positions worth $722M, up 7.2% from $673M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Great Point Partners's Q2 2018 filing shows 15 new, 11 increased, 7 reduced and 14 closed positions. Its largest new stake was Acadia Pharmaceuticals: 2,000,000 shares worth $30.5M. The largest sale was Arena Pharmaceuticals Inc, an estimated $43.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier.

  • Great Point Partners's largest Q2 2018 buy was Acadia Pharmaceuticals: 2,000,000 shares worth $30.5M.
  • Great Point Partners added most to Acceleron Pharma in Q2 2018, an estimated $10.8M increase.
  • Great Point Partners's biggest Q2 2018 reduction was Arena Pharmaceuticals Inc, cutting an estimated $43.1M.
  • Great Point Partners fully exited Zogenix, Inc. in Q2 2018, selling an estimated $39.2M.
  • Great Point Partners's ten largest holdings make up 55% of its $722M portfolio in Q2 2018.
  • Great Point Partners opened 15 new positions and closed 14 in Q2 2018.
  • Great Point Partners's portfolio value rose 7.2% quarter-over-quarter to $722M.

Based on Great Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.